Earnings call: GSK reports strong Q3 growth, optimistic for 2024

GSK (GlaxoSmithKline (NYSE:GSK) PLC) has reported a solid performance in its third-quarter earnings call, with CEO Emma Walmsley announcing a 9% sales growth and a 19% profit growth year-to-date. The… [+69425 chars]

Earnings call: GSK reports strong Q3 growth, optimistic for 2024

Earnings call: GSK reports strong Q3 growth, optimistic for 2024

Earnings call: GSK reports strong Q3 growth, optimistic for 2024

Earnings call: GSK reports strong Q3 growth, optimistic for 2024
Earnings call: GSK reports strong Q3 growth, optimistic for 2024
Ads Links by Easy Branches
Play online games for free at games.easybranches.com
Guest Post Services www.easybranches.com/contribute
Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs as the Company Embarks on a Pivotal Trial for its Investigational, Allogeneic CD7-Targeted CAR-T Cel
Biopreservation Market to Reach Market Valuation of USD 20.54 Billion by 2031 | SkyQuest Technology
Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech's Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate